Research and developmentof regenerative medicine products, such as iPS cells, and optimization of manufacturing and quality processes and supply systems. Supporting physician-initiated clinical trials of iPS cell-derived cardiomyocyte sheets conducted by Osaka University.
Strengths in culture and analysis technologies essential for development and commercialization of regenerative medicine products using iPS cell-derived cardiomyocytes based on research by Prof. Yoshiki Sawa (Osaka University)
Company name
Cuorips Inc.
Type of business
Medical(medical devices, drug discovery)
Representatives
Takayuki Kusanagi
Establishing a company
March 2017
Investment announcement date
March 2021 ,September 2026
Capitalist
Yoshiharu Asai ,Kan Yanazawa
HP
https://www.cuorips.co.jp/enPhasing
After Market
